ALZAI offers an AI-powered risk assessment tool for Alzheimer's Disease, enabling early detection and intervention. Their non-invasive screening identifies at-risk patients, stratifies risk by years, and quantifies risk with a confidence level, addressing the need for population-level screening. This allows healthcare providers, insurers, and pharmaceutical companies to improve care, efficiency, and clinical trial outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Early detection of Alzheimer's Disease is hampered by a lack of proactive screening, with current methods relying on physician suspicion and identifying only a small fraction of mild cognitive impairment (MCI) and mild Alzheimer's cases. This results in delayed intervention and missed opportunities for preventative care.
Solution
ALZAI offers an AI-driven platform for pre-symptomatic Alzheimer's Disease risk assessment, utilizing existing patient data to identify at-risk individuals up to 10 years before symptoms appear. The platform analyzes over 30 biomarkers present in common medical records to generate a risk profile, enabling earlier intervention and improved patient outcomes. By leveraging AI algorithms trained on longitudinal data from over 500,000 individuals, ALZAI increases the detection rates of mild MCI and AD, flagging at-risk patients for earlier diagnosis and preventative care. The non-invasive, low-cost screening solution integrates into existing healthcare workflows, providing a seamless experience for healthcare providers and stakeholders.
Target Audience
The primary target audience includes clinical trial companies seeking to pre-screen subjects, healthcare providers aiming to enhance patient care, healthcare payors looking to enable risk mitigation, and individuals seeking early insight into their Alzheimer's disease risk.
Features
- AI-powered risk assessment for Alzheimer's Disease using pre-existing patient data
- Identifies Alzheimer’s disease risk up to 10 years before symptoms appear
- Utilizes over 30 biomarkers present in common medical records
- Trained on longitudinal data of over 500,000 diverse individuals
- Demonstrates over 80% sensitivity in predicting Alzheimer's disease diagnoses
- Non-invasive and low-cost screening solution
- Web-based screening tool for clinical research and payor/provider applications